

Figure 1 Kaplan–Meier analysis to determine the time to progression (dotted line) and overall survival (solid line).

months (Table 4). In two of these trials conducted to evaluate the activity of first-line platinum-based combination chemotherapy, the treatment regimen included irinotecan (Culine *et al*, 2003; Briasoulis *et al*, 2008a). According to one, the combination of irinotecan plus cisplatin yielded an objective response rate of 38% and median OS of 6 months (Culine *et al*, 2003). In another study limited to poor-prognosis patients, irinotecan plus oxaliplatin yielded an objective response rate of 13% and median survival time of 9.5 months, with 40% of the patients still alive at 1 year (Briasoulis *et al*, 2008a). The patient background, especially the prognostic characteristics, may have an influence on the treatment outcome. Two-thirds of the patients in this study were prognostically good-risk patients, with a low percentage of patients having liver metastasis and a large percentage of patients with the disease extent being limited to the lymph nodes; in contrast, in most of the recently published series, the majority of the patients were prognostically poor-risk patients and/or had liver metastasis. Therefore, potential bias would make a reliable comparison of the results of the present and previous studies difficult.

Interestingly, the Kaplan–Meier analysis in this study revealed a 2-year survival rate of 27%, with some patients even showing long-term survival (Figure 1). The results of chemotherapy in a total of 1515 patients enrolled in 45 trials including 10 patients or more conducted between 1964 and 2002 showed that survival of the patients beyond 2 years was rare and that there were no cases of disease-free survival beyond 3 years (Pavlidis *et al*, 2003; Greco and Hainsworth, 2008). However, more recent studies have reported long-term survival in a small percentage of patients (Table 4). Long-term follow-up of the 396 patients enrolled in the five most recent studies revealed 1-, 2-, 3-, 5-, 8- and 10-year survival rates of 38, 19, 12, 11, 8 and 8% (Greco and Hainsworth, 2008). Although the reasons for the recent increase in long-term survival are uncertain, it is noteworthy that long-term survival was obtained with the combination of platinum agents and new agents.

The emergence of new non-platinum agents after 1995, including taxanes, gemcitabine, vinorelbine and irinotecan, has enabled the development of platinum-based combination chemotherapy for patients with CUP (Pavlidis *et al*, 2003). However, no definitive conclusions have been reached, because there is still no evidence based on randomised clinical trials to prove the superiority of the aforementioned combination chemotherapies over single-agent platinum therapy. In addition,

Table 3 Toxicity profiles (frequency > 10%)

Profile	Frequency (%)	No. of grade 3 (%)	No. of grade 4 (%)
<i>Haematologic toxicity</i>			
Leukopaenia	75.6	6 (13.3)	4 (8)
Neutropaenia	80	6 (13.3)	9 (20)
Anaemia	93.3	8 (17.8)	3 (6.7)
Thrombocytopenia	68.9	7 (15.6)	2 (4.4)
<i>Non-haematologic toxicity</i>			
Fatigue	60	0 (0)	0 (0)
Appetite loss	46.7	0 (0)	0 (0)
Nausea	82.2	1 (2.2)	0 (0)
Vomiting	26.7	1 (2.2)	0 (0)
Diarrhoea	57.8	4 (8)	0 (0)
Constipation	42.2	0 (0)	0 (0)
Skin rash	20	0 (0)	0 (0)
Febrile neutropaenia	13.3	5 (11.1)	1 (2.2)

the clinical benefits and risks of doublet and triplet combination chemotherapies are still uncertain. An attempt was made by European investigators to compare the effect of single-agent cisplatin with that of combined therapy with gemcitabine plus cisplatin on survival in good-risk patients with CUP. Although the results of this prospective trial were expected to clarify the role of combination chemotherapy in good-risk patients with CUP, the trial was stopped due to insufficient accrual, and the result showed a non-significantly higher survival with gemcitabine plus cisplatin as compared to that with cisplatin alone (Gross-Goupil *et al*, 2008).

Recently, standard chemotherapeutic regimens with or without molecular-targeting agents have been established for many cancers. Thus, there is a great demand to optimise the chemotherapeutic regimen for each patient with CUP. The approach based on the genomic characteristics may come to represent one of the breakthroughs in the proper use of chemotherapies tailored to individual patients.

In addition, the advances in the development of many molecular-targeted agents provide opportunities to explore various new combination therapies containing both cytotoxic and molecular-targeted agents for patients with CUP. Several studies have demonstrated the immunohistochemical expression of relevant molecular targets at high frequencies in tissue specimens (Massard *et al*, 2007). A phase II trial of bevacizumab plus erlotinib revealed substantial activity of this combination in patients treated previously or patients who had not received treatment because of the presence of poor-prognostic features (Hainsworth *et al*, 2007). In a preliminary study, treatment with paclitaxel plus carboplatin used in combination with bevacizumab plus erlotinib yielded an objective response rate of 48% ($N=19$ out of 40) and was well tolerated as first-line chemotherapy for patients with CUP (Greco *et al*, 2008). After first-line platinum-based combination chemotherapy, the approach of empiric second-line chemotherapy has shown little promise, with extremely low response rates (Hainsworth *et al*, 2001, 2005). Therefore, tailor-made first-line chemotherapy by genomic typing or addition of molecular-targeted drugs may be important in the treatment of CUP, which includes heterogeneous cancers, rather than the development of second-line chemotherapy.

In this study, the most frequently encountered toxicity was haematological toxicity and some patients needed blood transfusion or dose reduction of carboplatin. The dose delivery was fairly smooth in the chemotherapy-naïve patients with CUP as compared with that in our earlier phase I study of combined irinotecan plus carboplatin in patients with heavily treated ovarian cancer (Yonemori *et al*, 2005). Among the advantages of this regimen are

Table 4 Clinical trials of first-line regimens containing platinum agents reported in the literature from 2000

Group	Reference	Regimen	N	RR	MST (m)	1 year ^a	2 year ^b	
Doublet	Briasoulis et al (2000)	Carbo-P	77	38.7%	13.0	NA	NA	
	Voog et al (2000)	Cis-E	22	32%	8.0	NA	NA	
	Greco et al (2000a)	Cis-D	26	26%	8.0	40%	28%	
		Carbo-D	47	22%	8.0	33%	28%	
	Dowell et al (2001)	Carbo-E	17	19%	8.3	26%	NA	
	Saghatchian et al (2001)	Cis-E → Cis-E-B-I	30	40%	9.4	NA	28%	
		Cis-F	18	44%	16.1	NA	39%	
	Culine et al (2002b)	Dx-Cy ↔ Cis-E	82	39%	10.0	NA	NA	
	Culine et al (2003)	Cis-G	39	55%	8.0	NA	NA	
		Cis-Ir	40	38%	6.0	NA	NA	
	Park et al (2004)	Cis-P	37	42%	11.0	38%	11%	
	El-Rayes et al (2005)	Carbo-P	22	23%	6.5	27%	NA	
	Pittman et al (2006)	Carbo-G	51	30.5%	7.8	26%	12%	
	Briasoulis et al (2008a)	Ox-Ir	47	13%	9.5	40%	NA	
	Pentheroudakis et al (2008)	Carbo-D	47	32%	16.2	NA	NA	
	Triplet or more	This study	Carbo-Ir	45	41.9%	12.2	44%	27%
		Pamis et al (2000)	Cis-F-Ep	43	23%	5.8	NA	NA
		Greco et al (2000b)	Carb-P-E	71	48%	11.0	48%	20%
		Guardiola et al (2001)	Cis-Dx-Cy	22	50%	10.7	NA	NA
		Macdonald et al (2002)	Cis-F-Mit	31	27%	7.7	28%	10%
Greco et al (2002)		Carbo-G-P	113	25%	9.0	42%	23%	
Balaña et al (2003)		Cis-G-E	30	36.6%	7.2	26%	NA	
Piga et al (2004)		Carbo-Dx-E	102	26.5%	9.0	35.2%	18.1%	
Greco et al (2004)		Carbo-P-E → G-Ir	111	33%	9.1	35%	16%	
Palmeri et al (2006)		Cis-G-P	33	48.5%	9.6	NA	NA	
		Cis-G-V	33	42.3%	13.6	NA	NA	
Schneider et al (2007)		Carb-G-Cape	33	39.4%	7.6	35.6%	14.2%	
Greco et al (2008)		Carbo-P-Bv-Er	51	48%	11.3	NA	NA	

B = bleomycin; Bv = bevacizumab; Cape = capecitabine; Carbo = carboplatin; Cis = cisplatin; Cy = cyclophosphamide; D = docetaxel; Dx = doxorubicin; E = etoposide; Ep = epirubicin; Er = erlotinib; F = 5-FU; G = gemcitabine; I = ifosfamide; Ir = irinotecan; m = months; Mit = mitomycin C; MST = median survival time; NA = not available; Ox = oxaliplatin; P = paclitaxel; RR = response rate; V = vinorelbine. ^a1 year = 1-year survival rate. ^b2 year = 2-year survival rate.

that it is easy to adjust the irinotecan dose during each chemotherapy cycle according to the individual toxicity profiles and to manage the chemotherapy on an outpatient basis without prophylactic use of granulocyte-stimulating factor or erythropoietin.

In conclusion, combined irinotecan plus carboplatin chemotherapy appears to exert satisfactory activity and to be reasonably well tolerated in patients with CUP. Many conventional chemotherapies have been reported as the community standard of care for patients with CUP. This regimen was moderately well tolerated and may become established as one of the treatment options in patients with a good PS.

REFERENCES

Balaña C, Manzano JL, Moreno I, Cirauqui B, Abad A, Font A, Mate JL, Rosell R (2003) A phase II study of cisplatin, etoposide and gemcitabine in an unfavourable group of patients with carcinoma of unknown primary site. *Ann Oncol* 4: 1425-1429

Briasoulis E, Fountzilias G, Bamias A, Dimopoulos MA, Xiros N, Aravantinos G, Samantas E, Kalofonos H, Makatsoris T, Mylonakis N, Papakostas P, Skarlos D, Varthalitis I, Pavlidis N (2008a) Multicenter phase II trial of irinotecan plus oxaliplatin in patients with poor-prognosis cancer of unknown primary: a Hellenic cooperative oncology group study. *Cancer Chemother Pharmacol* 62: 277-284

Briasoulis E, Kalofonos H, Bafaloukos D, Samantas E, Fountzilias G, Xiros N, Skarlos D, Christodoulou C, Kosmidis P, Pavlidis N (2000) Carboplatin plus paclitaxel in unknown primary carcinoma; a phase II Hellenic Cooperative Oncology Group Study. *J Clin Oncol* 18: 3101-3107

Briasoulis E, Pavlidis N, Felip E (2008b) Cancers of unknown primary site: ESMO clinical recommendation for diagnosis, treatment and follow-up. *Ann Oncol* 19(Suppl 2): ii106-ii107

ACKNOWLEDGEMENTS

We thank Noboru Yamamoto, Yasuhiro Shimada and Eriko Nakano (National Cancer Center Hospital) for their assistance in the conduct of this study.

Conflict of interest

Katsumata N: Honoraria (Sanofi-aventis, Pfizer, Nippon Kayaku, Kyowa Hakkō Kogyo, Zeneca). His family members have no financial interest or conflict of interest in relation to this study. None of the authors or their immediate family members have any financial interest or conflict of interest in relation to this study.

Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME, Wiltshaw E (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. *J Clin Oncol* 7: 1748-1756

Cockcroft DW, Gault MH (1976) Prediction of creatine clearance from serum creatinine. *Nephron* 16: 31-41

Culine S, Fabbro M, Ychou M, Romieu G, Cupissol D, Pinguet F (2002b) Alternative bimonthly cycles of doxorubicin, cyclophosphamide, and etoposide, cisplatin with hematopoietic growth factor support in patients with carcinoma of unknown primary site. *Cancer* 94: 840-846

Culine S, Kramar A, Saghatchian M, Bugat R, Lesimple T, Lortholary A, Merrouche Y, Laplanche A, Fizazi K (2002a) Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of an unknown primary site. *J Clin Oncol* 20: 4679-4683

Culine S, Lortholary A, Voigt JJ, Bugat R, Théodore C, Priou F, Kaminsky MC, Lesimple T, Pivot X, Coudert B, Douillard JY, Merrouche Y,

- Allouache J, Goupil A, Négrier S, Viala J, Petrow P, Bouzy J, Laplanche A, Fizazi K (2003) Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study-trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01). *J Clin Oncol* 21: 3479–3482
- Dowell JE, Garrett AM, Shyr Y, Johnson DH, Hande KR (2001) A randomized phase II trial in patients with carcinoma of an unknown primary site. *Cancer* 91: 592–597
- El-Rayes BF, Shields AF, Zalupski M, Heilbrun LK, Jain V, Terry D, Ferris AM, Philip PA (2005) A phase II study of carboplatin and paclitaxel in adenocarcinoma of unknown primary. *Am J Clin Oncol* 28: 152–156
- Greco FA, Burris III HA, Erland JB, Gray JR, Kalman LA, Schreeder MT, Hainsworth JD (2000b) Carcinoma of unknown primary site. *Cancer* 89: 2655–2660
- Greco FA, Burris III HA, Litchy S, Barton JH, Bradof JE, Richards P, Scullin Jr DC, Erland JB, Morrissey LH, Hainsworth JD (2002) Gemcitabine, carboplatin, and paclitaxel for patients with carcinoma of unknown primary site: a Minnie Pearl Cancer Research Network study. *J Clin Oncol* 20: 1651–1656
- Greco FA, Burris III HA, Spigel DR, Thompson DS, Waterhouse DM, Hanson S, Vazquez ER, Hainsworth JD (2008) Paclitaxel/carboplatin plus bevacizumab/erlotinib as first-line treatment for patients with carcinoma of unknown primary site. *J Clin Oncol* 26(15S): 239s
- Greco FA, Erland JB, Morrissey LH, Burris III HA, Hermann RC, Steis R, Thompson D, Gray J, Hainsworth JD (2000a) Carcinoma of unknown primary site: phase II trials with docetaxel plus cisplatin or carboplatin. *Ann Oncol* 11: 211–215
- Greco FA, Hainsworth JD (2008) Cancer of unknown primary site. In *Cancer, Principle and Practice of Oncology*, De Vita VT, Lawrence TS, Rosenberg SA (eds), pp 2363–2387. Lippincott Williams and Wilkins: Philadelphia
- Greco FA, Rodriguez GI, Shaffer DW, Hermann R, Litchy S, Yardley DA, Burris III HA, Morrissey LH, Erland JB, Hainsworth JD (2004) Carcinoma of unknown primary site: sequential treatment with paclitaxel/carboplatin/etoposide and gemcitabine/irinotecan: a Minnie Pearl Cancer Research Network II phase trial. *Oncologist* 9: 644–652
- Gross-Goupil M, Fourcade A, Blot A, Penel N, Negrier S, Culine S, Moerrouche Y, Bouzy J, Laplanche A, Fizazi K (2008) A randomized trial of cisplatin with or without gemcitabine in patients with carcinoma of an unknown primary and without poor prognostic factors: results of the GEFCAPI02 trial. *Ann Oncol* 19(Suppl 8): vii248
- Guardiola E, Pivot X, Tchicknavorian X, Magne N, Otto J, Thyss A, Schneider M (2001) Combination of cisplatin–doxorubicin–cyclophosphamide in adenocarcinoma of unknown primary site: a phase II trial. *Am J Clin Oncol* 24: 372–375
- Hainsworth JD, Burris III HA, Calvert SW, Willcutt NT, Scullin Jr DC, Bramham J, Greco FA (2001) Gemcitabine in the second-line therapy of patients with carcinoma of unknown primary site: a II phase trial of the Minnie pearl cancer research network. *Cancer Invest* 19: 335–339
- Hainsworth JD, Spigel DR, Farley C, Thompson DS, Shipley DL, Greco FA (2007) Phase II trial of bevacizumab and erlotinib in carcinomas of unknown primary site: the Minnie pearl cancer research network. *J Clin Oncol* 25: 1747–1752
- Hainsworth JD, Spigel DR, Raefsky EL, Kuzur ME, Yost K, Kommar M, Litchy S, Greco FA (2005) Combination chemotherapy with gemcitabine and irinotecan in patients with previously treated carcinoma of unknown primary site: a Minnie pearl cancer research network phase II trial. *Cancer* 104: 1992–1997
- Kano Y, Akutsu M, Suzuki K, Yoshida M (1993) Effects of carboplatin in combination with other anticancer agents on human leukemia cell lines. *Leukemia Res* 17: 113–119
- Kano Y, Suzuki K, Akutsu M, Suda K, Inoue Y, Yoshida M, Sakamoto S, Miura Y (1992) Effects of CPT-11 in combination with other anticancer agents in culture. *Int J Cancer* 50: 604–610
- Macdonald AG, Nicolson MC, Samuel LM, Hutcheon AW, Ahmed FY (2002) A phase II study of mitomycin C, cisplatin and continuous infusion 5-Fluorouracil in the treatment of patients with carcinoma of unknown primary site. *Br J Cancer* 86: 1238–1248
- Massard C, Voigt JJ, Laplanche A, Culine S, Lortholary A, Bugat R, Theodore C, Priou F, Kaminsky MC, Lesimple T, Pivot X, Coudert B, Douillard JY, Merrouche Y, Fizazi K (2007) Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy? *Br J Cancer* 97: 857–861
- Misawa T, Kikkawa F, Maeda O, Obata NH, Higashide K, Suganuma N, Tomoda Y (1995) Establishment and characterization of acquired resistance to platinum anticancer drugs in human ovarian carcinoma cells. *Jpn J Cancer Res* 86: 88–94
- Mukai H, Watanabe T, Ando M, Katsumata N (2003) Unknown primary carcinoma: a feasibility assessment of combination chemotherapy with cisplatin and docetaxel. *Int J Clin Oncol* 8: 23–25
- Palmeri S, Lorusso V, Palmeri L, Vaglica M, Porta C, Nortilli R, Ferrau F, Comella G, Massidda B, Danova M (2006) Cisplatin and gemcitabine with either vinorelbine or paclitaxel in the treatment of carcinomas of unknown primary site: results of an Italian multicenter, randomized, phase II study. *Cancer* 107: 2898–2905
- Park YH, Ryou BY, Choi SJ, Yang SH, Kim HT (2004) A phase II study of paclitaxel plus cisplatin chemotherapy in an unfavourable group of patients with cancer of unknown primary site. *Jpn J Clin Oncol* 34: 681–685
- Parnis FX, Olver IN, Kotasek D, Norman J, Taylor A, Russell J, Patterson K, Keefe D, Marafioti T (2000) Phase II study of epirubicin, cisplatin and continuous infusion 5-fluorouracil for carcinoma of unknown primary site. *Ann Oncol* 11: 883–884
- Pavlidis N, Briasoulis E, Hainsworth J, Greco FA (2003) Diagnostic and therapeutic management of cancer of an unknown primary. *Eur J Cancer* 39: 1990–2005
- Pentheroudakis G, Briasoulis E, Kalofonos HP, Fountzilas G, Economopoulos T, Samelis G, Koutras A, Karina M, Xiros N, Samantas E, Bamias A, Pavlidis N (2008) Docetaxel and carboplatin combination chemotherapy as outpatient palliative therapy in carcinoma of unknown primary: a multicenter Hellenic cooperative oncology group phase II study. *Acta Oncologica* 47: 1148–1155
- Piga A, Nortilli R, Cetto GL, Cardarelli N, Luzi Fedeli S, Fiorentini G, D'Aprile M, Giorgi F, Parziale AP, Contu A, Montironi R, Gesuita R, Carle F, Cellerino R (2004) Carboplatin, doxorubicin and etoposide in the treatment of tumours of unknown primary site. *Br J Cancer* 90: 1898–1904
- Pittman KB, Olver IN, Koczwara B, Kotasek D, Patterson WK, Keefe DM, Karapetis CS, Parnis FX, Moldovan S, Yeend SJ, Price TJ (2006) Gemcitabine and carboplatin in carcinoma of unknown primary site: a phase 2 Adelaide Cancer Trials and Education Collaborative study. *Br J Cancer* 95: 1309–1313
- Saghathian M, Fizazi K, Borel C, Ducreux M, Ruffie P, Le Chevalier T, Theodore C (2001) Carcinoma of an unknown primary site: a chemotherapy strategy based on histological differentiation—results of a prospective study. *Ann Oncol* 12: 535–540
- Schneider BJ, El-Rayes B, Muler JH, Philip PA, Kalemkerian GP, Griffith KA, Zalupski MM (2007) Phase II trial of carboplatin, gemcitabine, and capecitabine in patients with carcinoma of unknown primary site. *Cancer* 110: 770–775
- Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. *J Natl Cancer Inst* 92: 205–216
- van der Gaast A, Verweij J, Planting AS, Hop WC, Stoter G (1996) Simple prognostic model to predict survival in patients with undifferentiated carcinoma of unknown primary site. *J Clin Oncol* 13: 1720–1725
- Voog E, Merrouche Y, Trillet-Lenoir V, Lassat C, Peaud PY, Rebattu P, Negrier S (2000) Multicentric phase II study of cisplatin and etoposide in patients with metastatic carcinoma of unknown primary. *Am J Clin Oncol* 23: 614–616
- Yakushiji S, Ando M, Yonemori K, Kohno T, Shimizu C, Katsumata N, Fujiwara Y (2006) Cancer of unknown primary site: review of consecutive cases at the National Cancer Center Hospital of Japan. *Int J Clin Oncol* 11: 421–425
- Yonemori K, Katsumata N, Yamamoto N, Kasamatsu T, Yamada T, Tsunenatsu R, Fujiwara Y (2005) A phase I study and pharmacologic evaluation of irinotecan and carboplatin for patients with advanced ovarian carcinoma who previously received platinum-containing chemotherapy. *Cancer* 104: 1204–1212

Bone metastasis and poor performance status are prognostic factors for survival of carcinoma of unknown primary site in patients treated with systematic chemotherapy

M. Kodaira¹, S. Takahashi^{1*}, S. Yamada¹, K. Ueda¹, Y. Mishima¹, K. Takeuchi², N. Yamamoto², Y. Ishikawa², M. Yokoyama¹, T. Saotome¹, Y. Terui¹ & K. Hatake¹

¹Department of Medical Oncology, Cancer Institute Hospital and ²Division of Pathology, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan

Received 18 May 2009; revised 30 August 2009; accepted 12 October 2009

Background: Cancer of unknown primary site (CUP) generally has a poor prognosis, and there is no established standard therapy. There have been no reports of a prognostic model for CUP patients treated with a single regimen of systemic chemotherapy.

Methods: Univariate and multivariate prognostic factor analysis for overall survival (OS) were conducted retrospectively in 58 consecutive CUP patients treated with carboplatin plus paclitaxel (Taxol) therapy as a first-line treatment.

Results: Univariate prognostic factor analysis revealed baseline performance status (PS) of two or more, low serum albumin level, pleural effusion, bone metastasis, and liver metastasis as adverse prognostic factors. Cox proportional hazards analysis showed that poor PS and bone metastasis had the most powerful adverse impact on survival. We developed a prognostic model using those two variables—a good-risk group (PS 0–1 without bone metastasis) and a poor-risk group (PS ≥ 2 or bone metastasis). The poor-risk group showed significantly poorer OS than the good-risk group (1 year OS 36.8% versus 67.1%, $P = 0.0003$).

Conclusions: Poor PS and bone metastasis were identified as independent adverse prognostic factors in CUP. A simple prognostic model was developed and seems useful for decision making as to whether chemotherapy is indicated for CUP patients.

Key words: cancer of unknown primary site, carboplatin plus paclitaxel, bone metastasis

Introduction

Cancer of unknown primary site (CUP) is pathologically diagnosed metastatic carcinoma in which no obvious primary site is identified with a conventional work-up. It is not a rare clinical entity, accounting for 3%–5% of all solid malignancies [1, 2]. The prognosis of CUP is generally considered poor, with median survival ~ 6 –12 months [3]. Briasoulis et al. [4] reported encouraging results from phase II data of carboplatin and paclitaxel combination therapy for patients with CUP. In this study, the overall response rate by an intention-to-treat analysis was 38.7%, and median overall survival (OS) was 13 months at median follow-up time of 28 months. Platinum and taxane combination therapy is now widely used in clinical practice [4–8], but recent multiple-treatment meta-analysis showed that no type of chemotherapy has been proven to

prolong survival in patients with CUP [9]. CUP consists of heterogeneous neoplasms with variable biological features, making it difficult to identify clinically useful prognostic survival factors. But several subsets have been identified requiring a specific treatment and having a better prognosis. Women with peritoneal carcinomatosis of serous adenocarcinoma [10], women with adenocarcinoma of axillary lymph nodes [11] or cervical lymph node metastasis of squamous cell carcinoma [12], young adults with poorly differentiated carcinoma of midline distribution [13], and undifferentiated carcinoma with neuroendocrine features [14] are CUP subgroups known to have a better prognosis. But the majority of CUPs have a poor prognosis, as mentioned above. In this article, we report the results of a prognostic factor analysis conducted in a population of 58 patients of CUP treated with carboplatin and paclitaxel as a first-line systemic chemotherapy. We retrospectively investigated baseline characteristics as prognostic factors for survival to identify a subset of patients who would benefit from chemotherapy.

*Correspondence to: Dr S. Takahashi, Department of Medical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo 135-8550, Japan. Tel: +81-3-3520-0111; Fax: +81-3-3570-0343; E-mail: stakahas@jfcr.or.jp

methods

patient characteristics

The medical and pathological records of 58 consecutive newly diagnosed patients with CUP who received carboplatin and paclitaxel (Taxol, Bristol-Myers Squibb, Tokyo, Japan) combination therapy as first-line therapy at the Cancer Institute Hospital, Japanese Foundation for Cancer Research, from March 2004 to January 2008 were retrospectively reviewed. Patients had pathologically confirmed metastatic cancer and were surveyed for detailed medical history, complete physical examination, blood counts, chemistry profile, chest radiograph, computed tomography (CT) scan of chest and abdomen, and further radiological survey or endoscopy of suspected areas. Serum prostate-specific antigen (PSA) was measured in male patients, and CA 125 was measured in female patients. Women with adenocarcinoma of axillary lymph nodes also received mammography and breast ultrasound. Young adults with poorly differentiated adenocarcinoma involving the mediastinal region were surveyed with α -fetoprotein and β -human chorionic gonadotropin. The gastrointestinal tracts of male and female patients with adenocarcinoma involving abdominal and pelvic lesion were surveyed by upper gastrointestinal endoscopy and colonoscopy. Gynecologic examination was carried out in female patients with abdominal and pelvic disease. Patients with squamous cell carcinoma of cervical lymph nodes also underwent laryngeal endoscopy and upper gastrointestinal endoscopy. Bone metastases were assessed by the combination of bone scintigraphy or positron emission tomography with chest X-ray, CT, or magnetic resonance imaging. Histopathological review including immunohistochemistry (IHC) was carried out to detect primary sites and to exclude other malignancies. Low-molecular cytokeratins (CKs) 7 and 20 were routinely stained for all patients with CUP, and thyroid transcription factor 1, caudal type homeobox transcription factor 2, and PSA were stained for patients with adenocarcinoma of CUP. When a specific origin was suspected by morphological examination and clinical history, distinctive IHC was carried out (chromogranin, synaptophysin, and CD56 for neuroendocrine cell carcinoma; D2-40, placental alkaline phosphatase, human chorionic gonadotropin, and CD30 for germ-cell tumor; and D2-40 and calretinin for mesothelioma). In the case of difficulty in diagnosing epithelial carcinoma, several IHC of S100, vimentin, leukocyte common antigen, and CKs are used for distinguishing melanoma, sarcoma, and lymphoma from the anaplastic cell type of carcinoma.

We excluded patients in favorable subsets that have specific treatments other than carboplatin and paclitaxel—such as women with adenocarcinoma of axillary lymph nodes or cervical lymph node metastasis of squamous cell carcinoma, young adults with poorly differentiated carcinomas of midline distribution, and patients with undifferentiated carcinomas of neuroendocrine features. However, women with peritoneal carcinomatosis of adenocarcinoma who were treated with carboplatin and paclitaxel as first-line treatment were included in this study.

treatment

Carboplatin was administered by a 2-h i.v. infusion, dosed with 6 mg/ml/min target area under the free carboplatin plasma concentration versus time curve and was followed by paclitaxel 200 mg/m² in 500 ml of normal saline administered over 3 h. The Calvert formula was used for carboplatin dosing, on the basis of a glomerular filtration rate calculated by the Cockcroft–Gault equation using serum creatinine, body surface area, and age. Chemotherapy cycles were repeated every 3 weeks and responding patients continued the chemotherapy until disease progression or intolerable toxicity. Response to chemotherapy was assessed by Response Evaluation Criteria In Solid Tumors (RECIST, version 1.0). Progression-free survival (PFS) and OS were calculated from day 1 of the first cycle of chemotherapy.

statistical analysis

Survival curves were estimated using the Kaplan and Meier method, compared using the log-rank test, and prognostic factors were identified by univariate analysis. Then the forward stepwise Cox proportional hazards analysis was carried out to identify independent prognostic factors. Statistical analyses were carried out using SPSS software (version 17.0; SPSS Inc., Chicago, IL).

results

patient characteristics

Patient characteristics are shown in Table 1. Fifty-eight CUP patients treated with at least one cycle of carboplatin and paclitaxel combination therapy were retrospectively analyzed. Twenty-eight (48.3%) patients were male, and the median age was 64 years (range 28–79 years). Forty-nine patients (84.5%) had a good performance status (PS) of zero to one. Twenty-six (44.8%) patients had well-differentiated adenocarcinoma, 21 (36.2%) patients had anaplastic or poorly differentiated carcinoma, and 5 patients (8.6%) had squamous cell carcinoma. Another six (10.3%) patients had clear-cell carcinoma, transitional cell carcinoma, or adenosquamous cell carcinoma. Metastatic sites are listed in Table 1. Lymph nodes, lung, bone, and liver were frequently involved sites and cervical, mediastinum, and retroperitoneum were common sites for lymph node metastasis.

PSA was measured in 20 male patients (median PSA level 2.04 ng/ml, range 0.34–4.04 ng/ml), and CA 125 was obtained in 26 female patients (median CA 125 level 462 U/ml, range 4.8–50000 U/ml). Five of six male patients with bone metastasis showed a PSA level <4.0 ng/ml, and the PSA value before treatment of one young male patient was not available.

outcome of chemotherapy

A total of 315 cycles were administered, and patients received a median of five cycles of treatment (range 1–21 cycles).

Table 1. Patient characteristics

Number of patients	58
Age, median (range)	64 (28–79)
Sex	
Male	28
Female	30
Performance status	
0–1	49
2–4	9
Pathology	
Adenocarcinoma	26
Squamous cell carcinoma	5
Poorly differentiated/anaplastic carcinoma	21
Other	6
Sites of metastasis	
Lung	15
Bone	13
Liver	11
Pleural effusion	15
Ascites	11
Lymph node	44

The response rates by main histopathological types of adenocarcinoma, squamous cell carcinoma, poorly differentiated carcinoma, or poorly differentiated adenocarcinoma were 42.3%, 60.0%, and 23.8%, respectively (Table 2). For other histology types, one patient with transitional cell carcinoma had partial response. Sixteen patients were treated with second-line chemotherapy. At a median follow-up time of 12 months (range 6–1659 days), median OS and PFS were 16.7 months and 5.9 months, respectively. Six patients had PFS >2 years and one of these patients survived >4 years.

prognostic model of clinical and biological variables

The outcome of univariate analysis of clinical and biological factors is listed in Table 3. Five parameters have prognostic relevance: poor PS (≥ 2) ($P = 0.01$), low serum albumin level (< 3.7 g/dl) ($P = 0.003$), pleural effusion ($P = 0.04$), bone metastasis ($P = 0.02$), and liver metastasis ($P = 0.02$). Multivariate analysis for these five variables was conducted and showed that bone metastasis ($P = 0.002$) and PS of two or more ($P = 0.016$) had significant adverse impact for survival (Table 3). Poor PS was not correlated with presence of bone metastasis.

Table 2. Treatment results

	N	CR (n)	PR (n)	ORR (%)
Total	58	5	15	34.5
Pathology				
Adenocarcinoma	26	5	6	42.3
Squamous cell carcinoma	6	0	3	50.0
Poorly differentiated anaplastic carcinoma	21	0	5	23.8

CR, complete response; PR, partial response; ORR, overall response rate.

Table 3. Univariate and multivariate analysis of prognostic factors for survival

	Univariate		Multivariate	
	P value	HR (95% CI)	P value	
PS ≥ 2	0.01	2.93 (1.22–7.04)	0.016	
Age (>65 years)	0.29			
Sex (male)	0.41			
ALP (>UNL)	0.13			
LDH (>UNL)	0.45			
ALB (<3.7 g/dl)	0.003			
Hb (<11.0 g/dl)	0.77			
Pleural effusion	0.04			
Ascites	0.69			
Lung metastasis	0.58			
Bone metastasis	0.02	3.48 (1.56–7.78)	0.002	
Liver metastasis	0.02			
Adenocarcinoma	0.81			
Poorly/anaplastic carcinoma	0.32			

HR, hazard ratio; CI, confidence interval; PS, performance status; ALP, alkaline phosphatase; UNL, upper normal limit; LDH, lactate dehydrogenase; ALB, albumin; Hb, hemoglobin.

The incidence of bone metastasis was not significantly different between males and females (6 of 28 males, 5 of 30 females). A prognostic model was developed with those two variables. Nineteen (32.8%) patients were assigned to the good-risk group (defined as PS 0–1 without bone metastasis), and 38 (67.2%) patients were assigned to the poor-risk group (defined as PS ≥ 2 or bone metastasis). The poor-risk group ($n = 19$) showed significantly poorer OS than good-risk group ($n = 39$) (1 year OS 36.8% versus 67.1%, $P = 0.0003$) (Figure 1).

discussion

To identify a favorable or poor prognostic group of patients with CUP is of great concern when physicians consider whether systemic chemotherapy is indicated. No randomized trial showed better survival with chemotherapy than best supportive care. To our knowledge, the current study is the first that assesses prognostic factors for survival of patients with CUP treated with a single first-line regimen and should give us information as we choose an optimal therapy.

We demonstrated an overall response rate of 34.5% and a median OS of 16.7 months in CUP patients by an intention-to-treat analysis. This result seems similar to the results previously reported by Briasoulis et al. [4] and slightly better than other reports. One reason might be that both studies included female patients with peritoneal carcinomatosis (11 of 58 in ours and 19 of 75 in Briasoulis et al.). In our study, seven women (63.6%) responded to chemotherapy. A second reason might be that our group included a marginally larger number of patients with good PS. Goulinopoulos et al. [9] reported in recent multiple-treatment meta-analysis for CUP that 10 randomized trials assessed in that study included variable rates for patients with poor PS (median 24.5%, interquartile range 12.8%–38.9%). Third, our study included a slightly smaller number of patients




Figure 1. The prognostic model incorporating two variables. The good-risk group ($n = 39$) was defined as performance status (PS) of zero to one without bone metastasis and the poor-risk ($n = 19$) group as PS of two or more, or bone metastasis.

with liver metastasis, which was reported as an independent poor prognostic factor by Seve et al. [15]. But the rates of liver metastases in previous studies are variable from 16% to 76% [4–8, 16, 17]. The patients in the present study were treatable with combination therapy, so most of them maintained good PS and end organ function. No prospective studies or meta-analysis of prognostic factors for CUP have been published. But several retrospective studies have shown a number of independent adverse factors such as age, male gender, poor PS, adenocarcinoma histology, number of metastatic sites, liver metastasis, bone metastasis, lung metastasis, pleural metastasis, brain metastasis, comorbidity scoring of adult comorbidity evaluation-27 (ACE-27), low serum albumin, high serum lactate dehydrogenase (LDH), high serum alkaline phosphatase, lymphopenia, anemia, thrombocytopenia, high serum carcinoembryonic antigen, and high serum CA 125 [15, 18–20]. Abbruzzese et al. [18] reported adverse prognostic variables from a study of 657 cases of CUP at M. D. Anderson Cancer Center, and multivariate analysis identified male gender, a large number of metastatic sites, adenocarcinomatous histological type, and the presence of liver metastasis as unfavorable indicators. Culine et al. [19] proposed a simple prognostic model using PS and serum LDH levels in a population of 150 CUP patients, excluding favorable subsets, at a French cancer center. More recently, Seve et al. conducted a retrospective study assessing the influence of comorbidities, age, PS, and chemotherapy on survival in a population of 389 patients with CUP in Canada. Multivariate analysis showed that patients who had a PS of two or more and a high overall ACE-27 score had a poor prognosis. They concluded that the impact of comorbidity on survival was limited to patients with low PS [20]. The same author showed in another study that low serum albumin level and liver metastasis were the two most powerful adverse prognostic factors. The prognostic significance of those two factors was validated in another set of 124 patients with CUP [15]. In our study, bone metastases and poor PS (≥ 2) had a powerful adverse impact on survival. In clinical practice, bone metastases could be the cause of declining PS, but in this study, bone metastases and poor PS were not significantly correlated. Poor PS was also an adverse prognostic factor in studies by Culine et al. and by Seve et al. Bone metastases have been identified as an independent poor prognostic factor for the first time in uniformly treated patients with CUP. Prognostic significance of bone metastases in advanced cancer depends on the primary sites. In breast cancer or prostate cancer, the presence of bone metastases or bone-only metastases indicates a better prognosis [21]. On the other hand, the presence of bone metastases indicates a worse prognosis in lung cancer [22], thyroid cancer [23], or renal cell carcinoma [24]. The worse prognosis of patients with bone metastases in our series might be due to the apparent absence of occult breast cancer or prostate cancer in this set of patients.

Although our study might be small for finding independent prognostic factors retrospectively, it is important to identify clinically useful prognostic factors for CUP patients treated with platinum and taxane combination therapy, which are used frequently in daily practice. It has not been proven that systemic chemotherapy would prolong the survival of unfavorable CUP patients, and the best supportive care is a reasonable choice for patients who have little benefit from systemic chemotherapy.

We designed a new prognostic model that incorporated those two factors, poor PS and bone metastasis. The OS of patients with at least one or more prognostic factor was significantly shorter than those with no adverse prognostic factor. This model might be useful for decision making regarding the use of chemotherapy for CUP patients in daily clinical practice. A validation study of our prognostic model is warranted in the near future.

funding

A Health and Labour Sciences Research grant from the Ministry of Health, Labour and Welfare of Japan (2007-Clinical Cancer Research-029).

acknowledgements

The authors are grateful to staff members including Sayuri Nishiyama, Eriko Nara, Hiroaki Asai, Atsushi Katsube, and Hiroaki Goto for treating the patients at the Cancer Institute Hospital. Author contributions: MK designed the study, treated the patients, collected clinical data, and wrote the paper; SY and KU treated the patients and collected clinical data; KT, NY and YI diagnosed pathological specimens; YM, MY and YT treated the patients and assisting with writing the paper; KH designed the study and supervised the writing of the paper; ST treated the patients and designed the study and supervised all aspects of the research and analysis and contributed to the paper.

disclosure

The funding was coordinated by K. Nakagawa, Kinki University, Osaka, Japan.

references

- Briasoulis E, Pavlidis N. Cancer of unknown primary origin. *Oncologist* 1997; 2: 142–152.
- Van de Wouw AJ, Janssen-Heijnen ML, Coebergh JW et al. Epidemiology of unknown primary tumours; incidence and population-based survival of 1285 patients in Southeast Netherlands, 1984–1992. *Eur J Cancer* 2002; 38(3): 409–413.
- Hainsworth JD, Greco FA. Treatment of patients with cancer of an unknown primary site. *N Engl J Med* 1993; 329: 257–263.
- Briasoulis E, Kalofonos H, Bafaloukos D et al. Carboplatin plus paclitaxel in unknown primary carcinoma: a phase II Hellenic Cooperative Oncology Group Study. *J Clin Oncol* 2000; 18: 3101–3107.
- Pentheroudakis G, Briasoulis E, Kalofonos HP et al. Docetaxel and carboplatin combination chemotherapy as outpatient palliative therapy in carcinoma of unknown primary: a multicentre Hellenic Cooperative Oncology Group phase II study. *Acta Oncol* 2008; 47: 1148–1155.
- Berry W, Elkordy M, O'Rourke M et al. Results of a phase II study of weekly paclitaxel plus carboplatin in advanced carcinoma of unknown primary origin: reasonable regimen for community-based clinic? *Cancer Invest* 2007; 25: 27–31.
- Hainsworth JD, Erland JB, Kalman LA et al. Carcinoma of unknown primary site: treatment with 1-hour paclitaxel, carboplatin, and extended schedule etoposide. *J Clin Oncol* 1997; 15: 2385–2393.
- Huebner G, Link H, Kohne CH et al. Paclitaxel and carboplatin vs gemcitabine and vinorelbine in patients with adeno- or undifferentiated carcinoma of unknown primary: a randomized prospective phase II trial. *Br J Cancer* 2009; 100: 44–49.
- Gollinopoulos V, Pentheroudakis G, Salanti G et al. Comparative survival with diverse chemotherapy regimens for cancer of unknown primary site: multiple-treatments meta-analysis. *Cancer Treat Rev* 2009; 35: 570–573.

10. Ransom DT, Patel SR, Keeney GL et al. Papillary serous carcinoma of the peritoneum. A review of 33 cases treated with platin-based chemotherapy. *Cancer* 1990; 66: 1091–1094.
11. Rosen PP. Axillary lymph node metastases in patients with occult noninvasive breast carcinoma. *Cancer* 1980; 46: 1298–1306.
12. Jesse RH, Perez CA, Fletcher GH. Cervical lymph node metastasis: unknown primary cancer. *Cancer* 1973; 31: 854–859.
13. van der Gaast A, Verweij J, Henzen-Logmans S et al. Carcinoma of unknown primary: identification of a treatable subset? *Ann Oncol* 1990; 1: 119–122.
14. Hainsworth JD, Johnson DH, Greco FA. Cisplatin-based combination chemotherapy in the treatment of poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary site: results of a 12-year experience. *J Clin Oncol* 1992; 10: 912–922.
15. Seve P, Ray-Coquard I, Trillet-Lenoir V et al. Low serum albumin levels and liver metastasis are powerful prognostic markers for survival in patients with carcinomas of unknown primary site. *Cancer* 2006; 107: 2698–2705.
16. Palmeri S, Lorusso V, Palmeri L et al. Cisplatin and gemcitabine with vinorelbine or paclitaxel in the treatment of carcinomas of unknown primary site: results of an Italian multicenter, randomized, phase II study. *Cancer* 2006; 107: 2898–2905.
17. Pittman KB, Olver IN, Koczwara B et al. Gemcitabine and carboplatin in carcinoma of unknown primary site: a phase 2 Adelaide Cancer Trials and Education Collaborative study. *Br J Cancer* 2006; 95: 1309–1313.
18. Abbruzzese JL, Abbruzzese MC, Hess KR et al. Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patient. *J Clin Oncol* 1994; 12: 1272–1280.
19. Culine S, Kramar A, Saghachian M et al. Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of an unknown primary. *J Clin Oncol* 2002; 20: 4679–4683.
20. Seve P, Sawyer M, Hanson J et al. The influence of comorbidities, age, and performance status on the prognosis and treatment of patients with metastatic carcinomas of unknown primary site: a population-based study. *Cancer* 2006; 106: 2058–2066.
21. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. *Clin Cancer Res* 2006; 12: 6243–6249.
22. Herndon JE 2nd, Kornblith AB, Holland JC, Paskett ED. Patient education level as a predictor of survival in lung cancer clinical trials. *J Clin Oncol* 2008; 26: 4116–4123.
23. Shoup M, Stojadinovic A, Nissan A et al. Prognostic indicators of outcomes in patients with distant metastases from different thyroid carcinoma. *J Am Coll Surg* 2003; 197: 191–197.
24. Négrier S, Escudier B, Gomez F et al. Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d'Immunothérapie. *Ann Oncol* 2003; 13: 1460–1468.

Meta-Analysis of Single Agent Chemotherapy Compared With Combination Chemotherapy as Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer

Massimo Di Maio, Paolo Chiadini, Vassilis Georgoulas, Dora Hatzidaki, Koji Takeda, Floris M. Wachters, Vittorio Gebbia, Egbert F. Smit, Alessandro Morabito, Ciro Gallo, Francesco Perrone, and Cesare Gridelli

From the Clinical Trials Unit, National Cancer Institute; Department of Medicine and Public Health, Second University of Napoli; Division of Medical Oncology, "N.Giannettasio" Hospital, Rossano, La Maddalena, University of Palermo, Division of Medical Oncology, "S. Giuseppe Moscati" Hospital, Avellino, Italy; Department of Medical Oncology, University General Hospital, Heraklion, Crete, Greece; Osaka City General Hospital, Osaka, Japan; Department of Pulmonology, University Medical Center, Groningen; and Department of Pulmonary Diseases, Vrije Universiteit Medical Centre, Amsterdam, the Netherlands.

Submitted April 7, 2008; accepted November 21, 2008; published online ahead of print at www.jco.org on March 9, 2009.

M.D.M. and P.C. contributed equally to this work.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

Corresponding author: Cesare Gridelli, MD, Division of Medical Oncology, "S.G. Moscati" Hospital, Contrada Amoretta, 83100 Avellino, Italy; e-mail: cgridelli@libero.it.

© 2009 by American Society of Clinical Oncology

0732-183X/09/2799-1/\$20.00

DOI: 10.1200/JCO.2008.17.5844

A B S T R A C T

Purpose

Doublet chemotherapy is more effective than single-agent as first-line treatment of advanced non-small-cell lung cancer (NSCLC). As second-line treatment, several randomized trials have been performed comparing single-agent with doublet chemotherapy, but each trial had an insufficient power to detect potentially relevant differences in survival.

Methods

We performed meta-analysis of individual patient data from randomized trials, both published and unpublished, comparing single-agent with doublet chemotherapy as second-line treatment of advanced NSCLC. Primary end point was overall survival (OS). All statistical analyses were stratified by trial.

Results

Eight eligible trials were identified. Data of two trials were not available, and data of six trials (847 patients) were collected. Median age was 61 years. Performance status was 0 or 1 in 90%; 80% of patients had received previous platin-based chemotherapy. OS was not significantly different between arms ($P = .32$). Median OS was 37.3 and 34.7 weeks in the doublet and single-agent arms, respectively. Hazard ratio (HR) was 0.92 (95% CI, 0.79 to 1.08). Response rate was 15.1% with doublet and 7.3% with single-agent ($P = .0004$). Median progression-free survival was 14 weeks for doublet and 11.7 weeks for single agent ($P = .0009$; HR, 0.79; 95% CI, 0.68 to 0.91). There was no significant heterogeneity among trials for the three efficacy outcomes. Patients treated with doublet chemotherapy had significantly more grade 3 to 4 hematologic (41% v 25%; $P < .0001$) and grade 3 to 4 nonhematologic toxicity (28% v 22%; $P = .034$).

Conclusion

Doublet chemotherapy as second-line treatment of advanced NSCLC significantly increases response rate and progression-free survival, but is more toxic and does not improve overall survival compared to single-agent.

J Clin Oncol 27. © 2009 by American Society of Clinical Oncology

INTRODUCTION

Cisplatin-based chemotherapy is considered standard of care worldwide for patients with advanced non-small-cell lung cancer (NSCLC).¹ At disease progression, many patients still have a good performance status (PS) and can be considered for further active treatment.

Until 2000, there was no evidence supporting the efficacy of second-line treatment, but in recent years the efficacy of several drugs in this setting has been demonstrated in phase III trials, and second-line treatment is now considered standard.^{2,3}

In particular, second-line chemotherapy with docetaxel 75 mg/m² every 3 weeks has been proven

to be effective in two phase III trials.^{4,5} This treatment, indeed, prolongs overall survival (OS) compared with best supportive care, and improves some quality of life items like fatigue and pain.⁴ In a individual patient data meta-analysis,⁶ weekly docetaxel demonstrated similar efficacy, with a significantly lower risk of febrile neutropenia. Pemetrexed has been shown to be comparable with docetaxel, with a more favorable toxicity profile.⁷ To date, no single-agent treatment has obtained better results than docetaxel.

A logical strategy for improving the efficacy of second-line treatment is to combine agents with different mechanism of action and toxicity. In first-line treatment, doublet chemotherapy is more effective

than single-agent, both in terms of objective response and OS.⁸ Several randomized trials comparing a doublet with single-agent chemotherapy as second-line have been conducted in recent years.⁹⁻¹⁵ Most of these trials were characterized by a small sample size, with inadequate statistical power to exclude potentially clinically relevant differences in efficacy.

The main objective of this meta-analysis, based on individual patient data, is to compare the efficacy of a doublet chemotherapy with single-agent treatment for the second-line treatment of advanced NSCLC, with a statistical power much higher than each trial. Data regarding activity and toxicity were also collected and analyzed.

PATIENTS AND METHODS

Identification of Eligible Trials

Published and unpublished studies were included in this meta-analysis, as previously recommended.¹⁶

The literature search was performed in July 2007, and updated in June 2008, to identify all randomized trials comparing single-agent and combination chemotherapy in second-line treatment of patients with advanced NSCLC. Trials evaluating a combination of a cytotoxic agent with a targeted drug, or a combination of targeted agents were not eligible. Search was performed using PubMed, EMBASE, Proceedings of American Society of Clinical Oncology, Proceedings of European Society of Medical Oncology, Proceedings of European Cancer Conference, Proceedings of World Conference on Lung Cancer, and the registry of the U.S. National Institutes of Health clinicaltrials.gov from 1997 to 2008, with the following key-words: "lung cancer", "NSCLC"; "second-line", "randomized/randomized". References of the identified articles were checked, and principal investigators were asked whether they were aware of other published or unpublished trials.

Study Quality

Each study was assessed for quality and potential bias using a structured checklist based on the Method for Evaluating Research and Guideline Evidence criteria.¹⁷ Study characteristics were quality of randomization, blinding, outcome measures, measure assessment, arm comparability, loss to follow-up, and intention to treat analysis. An overall quality score was assigned to each

Table 1. Characteristics of the Six Randomized Trials Included in the Meta-Analysis

Parameter	Study					
	Takeda et al ⁹	Georgoulas et al ¹⁰	Georgoulas et al ¹¹	Wachters et al ¹²	Gebbia et al ¹⁴	Smit et al ¹⁵
Phase of the study	III	II*	II*	II	III	II*
Treatment dose and schedule						
Single-agent arm	Docetaxel 60 mg/m ² day 1 every 3 weeks	Irinotecan 300 mg/m ² day 1 every 3 weeks	Cisplatin 80 mg/m ² day 1 every 3 weeks	Docetaxel 75 mg/m ² day 1 every 3 weeks	Docetaxel 33.3 mg/m ² days 1, 8, 15 every 4 weeks	Pemetrexed 500 mg/m ² day 1 every 3 weeks
Combination arm	Docetaxel 60 mg/m ² day 8 + gemcitabine 800 mg/m ² days 1 and 8 every 3 weeks	Gemcitabine 1,000 mg/m ² days 1 and 8 + irinotecan 300 mg/m ² day 8 every 3 weeks	Cisplatin 80 mg/m ² day 8 + irinotecan 110 mg/m ² day 1, 100 mg/m ² day 8, every 3 weeks	Docetaxel 60 mg/m ² day 1 + irinotecan 200 mg/m ² day 1 every 3 weeks	Docetaxel 30 mg/m ² days 1, 8, 15 every 4 weeks + gemcitabine 800 mg/m ² days 1 and 8 every 4 weeks or vinorelbine 20 mg/m ² days 1 and 8 every 4 weeks or capecitabine 1,300 mg/m ² days 5 to 18 every 4 weeks	Pemetrexed 500 mg/m ² day 1 every 3 weeks + carboplatin AUC5 day 1 every 3 weeks
Primary end point	Overall survival	Overall survival	Overall survival	Response rate	Overall survival	Time to progression
Planned sample size	284	144	130	106	375	240
Actual sample size	130	147	139	108	84	240
Start of the accrual	January 2002	September 1999	July 1999	October 2000	May 2005	October 2005
End of the accrual	April 2003	December 2001	November 2002	January 2003	December 2006	May 2007
Median follow-up, weeks	90.4	59.4	91.6	74.3	70.7	64.0
Trial quality (MERGE criteria)	B1	B1	B1	B1	B1	B1
Eligibility criteria						
Age	20-75	≥ 18	≥ 18	≥ 18	18-75	≥ 18
Performance status	ECOG 0-1	WHO 0-2	WHO 0-2	ECOG 0-2	ECOG 0-2	ECOG 0-2
Previous lines of chemotherapy	1	1-2	1-2	1	1	≥ 1
Previous treatment	Platin based	Platin based	Taxane + gemcitabine	Platin- or nonplatin-based	Platin based	Relapse > 3 months after platin based

Abbreviations: AUC5, area under the time concentration curve 5; MERGE, Method for Evaluating Research and Guideline Evidence; ECOG, Eastern Cooperative Oncology Group.
*Defined randomized phase II, sample size was actually calculated according to phase III design, with formal comparison between treatment arms.

study: A (low risk of bias), B1 (low to moderate risk of bias), B2 (moderate to high risk of bias), C (high risk of bias).

Before performing the analyses, data of each published study were carefully checked and verified for coherence with the original publications; data-base quality was excellent for all studies.

Statistical Methods

All the analyses were performed according to the intention-to-treat principle. All the analyses were stratified by trial. All tests were two sided.

Primary end point was OS, defined as the time between date of random assignment and date of death, or last date of follow-up for censored patients. OS curves were estimated using the Kaplan-Meier technique and compared using the stratified log-rank test. Median follow-up was calculated according to the inverted Kaplan-Meier technique.¹⁸

Because meta-analysis was based on individual patient data, heterogeneity of treatment effect among trials on OS was assessed by likelihood ratio of two trial-stratified models, one with trial-specific treatment estimates and one with overall treatment estimate, as suggested by Smith et al.¹⁹ Under the null hypothesis of no heterogeneity, this statistic follows approximately a χ^2 distribution on $J - 1$ df (where J is the total number of trials).¹⁹

Findings of the meta-analysis are depicted in classical Forest plots, with point estimates and 95% CIs for each trial and overall; size of the squares is proportional to study size.

Further exploratory analyses were performed in the subgroups based on the main baseline patients characteristics, to describe possible heterogeneity of treatment effect. Interaction test was also performed.

Secondary end points were progression-free survival (PFS), objective response rate (RR), and toxicities.

PFS was defined as the time between date of random assignment and date of progression, or date of death for patients dead without progression, or last date of follow-up for censored patients. PFS was analyzed likewise OS.

RR was compared using the stratified Mantel-Haenszel χ^2 test for combining 2×2 tables and the Breslow-Day test was used to detect differences in treatment effect among the trials.²⁰ For RR, patients obtaining complete response or partial response were considered as responders, and all others as nonresponders.

Toxicity variables were dichotomized as severe (grade 3 to 4) and no/mild (grades 0 to 2). Toxicity rates were compared using the stratified exact tests; the Zelen exact test was used to detect differences in toxicity effects among the six trials²⁰ and the pooled odds ratio (OR) with 95% CI was estimated by means of exact method.

Statistical analyses were performed using SAS 8.2 (SAS Institute, Cary, NC) and graphs using R 2.4.1 (R Foundation for Statistical Computing, Vienna, Austria) software packages. Exact tests were performed using StatXact 7 (Cytel Software, Cambridge, MA).

RESULTS

Characteristics of the Trials

Eight trials were eligible, for a total of 1,372 patients: three trials were conducted in Greece,^{10,11,13} two in the Netherlands,^{12,15} one in Japan,⁹ one in Italy,¹⁴ and one in Canada, the United States, and Poland (GlaxoSmithKline, data on file, courtesy of P. Legenne). As of February 2009, six trials have already been published as full-length articles⁹⁻¹⁴; one was presented at the 2008 Annual Meeting of the American Society of Clinical Oncology,¹⁵ and one is still unpublished.

Individual patient data from one trial,¹³ despite the efforts of the principal investigator who moved to another institution, were not available. We also did not obtain individual patient data from the

Table 2. Characteristics of the Patients Analyzed (N = 847)

Characteristic	Single Agent (n = 428)		Combination (n = 419)		Total (N = 847)	
	No.	%	No.	%	No.	%
Median age, years	61		60		61	
Range	34-78		34-84		34-84	
Sex						
Male	326	76	324	77	650	77
Female	102	24	95	23	197	23
Histologic type						
Adenocarcinoma	204	48	182	43	386	46
Squamous	124	29	132	32	256	30
Large cell	49	11	60	14	109	13
Non-small cell unspecified	30	7	31	7	61	7
Other	2	1	—	—	2	< 1
Unknown	19	6	14	3	33	4
Performance status						
0	130	30	128	31	258	30
1	250	58	253	60	503	59
2	48	11	38	9	86	10
Previous chemotherapy						
Cisplatin	240	56	239	57	479	57
Carboplatin	103	24	106	25	209	25
Platin based	342	80	332	79	674	80
Docetaxel	143	33	156	37	299	35
Paclitaxel	22	5	25	6	47	6
Gemcitabine	253	59	200	48	453	53
Vinorelbine	29	7	38	9	67	8
Response to first line						
Responders	210	49	203	48	413	49
Non-responders	213	50	212	51	425	50
Unknown	5	1	4	1	9	1

unpublished SKF104864-615 trial (unpublished results), although GlaxoSmithKline, sponsor of the trial, kindly provided us with a summary of final results. Eventually individual data were obtained from six trials, accounting for 63% of the potentially eligible patients (863 of 1,372). Main characteristics of the six trials are described in Table 1. Four were randomized phase II trials,^{10-12,15} but in three of these^{10-11,15} sample size was actually calculated according to a classical phase III design, with a formally planned comparison between treatment arms. The Japanese trial⁹ was terminated early, because of high incidence of interstitial lung disease (ILD) and three treatment-related deaths (5%) due to ILD in the combination arm. In the Italian trial,¹⁴ patients were randomly assigned in a 3:1:1 ratio to three arms: A, docetaxel; B, docetaxel plus gemcitabine or plus vinorelbine; C, docetaxel plus capecitabine. For this meta-analysis, arms B and C were grouped. The trial was stopped prematurely, blind to results, because the recruitment rate was extremely slower than expected.

Single agent consisted of docetaxel (three trials), irinotecan (one trial), cisplatin (one trial), pemetrexed (one trial). In all trials, patients assigned to combination chemotherapy were treated with the addition of a second drug to the one administered as single-agent. Except Nederlandse Vereniging van Artsen voor Longziekten en Tuberculose trial 7,¹⁵ which evaluated pemetrexed plus carboplatin in patients already treated with platin-based therapy, all the trials evaluated drugs not received by the patients as first-line treatment.

Methodological Quality of the Trials

In all studies, most evaluation criteria from the checklist are fulfilled with overall quality score B1 (Table 1; ie, all included studies were of sufficiently high quality to consider the risk of bias as low to moderate). The main drawback of all studies was the lack of blinding, which is a common practice in clinical trials in advanced cancer because of difficulties of blinding to different infusion times, schedules, and toxicities. Lack of blinding is unlikely to affect OS, but could potentially bias secondary end points (PFS, RR, toxicity). All studies had a time-to-event primary outcome, with the exception of Wachters et al study,¹² that had RR as a primary end point. Definitions of the primary outcome were detailed in all trials. Allocation concealment was always adequate. Treatment groups were balanced for the most relevant baseline characteristics (age, PS, stage, histology, response to first-line treatment), although these characteristics were not always considered as stratification factors. For all trials, complete data were available for intention-to-treat analysis, and reasons for the exclusion of a few patients were carefully accounted for and are described later. In particular, a very small percentage of patients were completely lost to follow-up after random assignment in two trials.^{10,11}

Main Results

Overall, 847 of the 863 originally randomly assigned patients were eligible for the meta-analysis (Appendix Fig A1, online only). Fifteen patients were excluded from two trials^{10,11} because of complete absence of information in the study database. One patient was excluded because of ineligible histology (small-cell lung cancer). Of the 847 eligible patients, 428 patients (50.5%) had been assigned to a single agent, and 419 were assigned to doublet (49.5%). Main characteristics of the 847 patients are described in Table 2. Median age was 61 years (range, 34 to 84). Most of the patients were males (77%), had a good PS (0 or 1 in 90%), and had previously received a first-line platin-based treatment (80%).

Median follow-up was 74.0 weeks (71.7 weeks in single-agent arm, and 74.4 weeks in combination arm). Overall survival curves of patients according to treatment arms are shown in Figure 1. Overall, 642 deaths were recorded (76%), with median survival equal to 37.3 weeks for doublet, and 34.7 weeks for single agent. Corresponding hazard ratio (HR) was 0.92 (95% CI, 0.79 to 1.08; $P = .32$ at log-rank test stratified by trial). The 6-month survival rates were 62.9% and 61.6%, and the 1-year survival rates were 34.4% and 31.8%, for combination and single agent chemotherapy, respectively. As shown in Figure 2, there was no evidence of heterogeneity among the six trials ($P = .87$; I^2 0%). Exploratory survival analysis by subgroups is shown in Figure 3; there was no evidence of heterogeneity among subgroups of treatment effect around the overall effect.

PFS curves of patients according to treatment assigned are shown in Figure 1. Overall, 805 progressions were recorded (95%), with median PFS equal to 14.0 weeks and 11.7 weeks for doublet and single-agent chemotherapy, respectively. The corresponding HR was 0.79 (95% CI, 0.68 to 0.91; $P = .0009$ at log-rank test stratified by trial). Six-month PFS rates were 27.2% and 18.1%, and the 1-year PFS rates were 6.5% and 5.5% for patients assigned to combination and single-agent chemotherapy, respectively. Forest plot of treatment effect on




Fig 1. (A) Overall survival (OS) and (B) progression-free survival (PFS) curves by treatment arm. Pts, patients.




Fig 2. Forest plot of treatment effect on (A) overall survival and (B) progression-free survival. (O-E), observed events minus expected events.

PFS is shown in Figure 2. There was no statistically significant heterogeneity among the six trials ($P = .094$; I^2 47%) and among subgroups (Fig 3).

Further posthoc analyses were performed to study interaction between trial characteristics and treatment effect (Appendix Table A1, online only). Trials were classified according to the single-agent drug (docetaxel^{9,12,14} v other drug^{10,11,15}), or according to the dose planned in doublet arm (same dose of the single-agent drug^{9-11,15} v reduced dose^{12,14}). Interaction tests for OS were not significant. PFS was significantly longer with doublet only when single-agent drug was used at the same dose in the doublet arm.

Objective RR was increased with doublet: 7.3% versus 15.1%, with single-agent and doublet, respectively ($P = .0004$). The test for heterogeneity was borderline significant ($P = .06$; I^2 50%). Exact odds ratio of RR was 2.24 (95% CI, 1.43 to 3.53; Appendix Fig A2, online only).

A summary of grade 3 to 4 adverse effects is reported in Table 3. Combination chemotherapy is characterized by a significantly higher incidence of neutropenia, anemia, thrombocytopenia, emesis, and diarrhea. Patients treated with doublet had significantly more grade 3 to 4 hematologic (25% v 41%; $P < .0001$) and grade 3 to 4 nonhematologic toxicity (22% v 28%; $P = .034$). Heterogeneity among studies was found for some adverse effects, possibly due to the different drugs and doses used.

DISCUSSION

This individual patient data meta-analysis shows no significant difference in OS between doublet and single-agent chemotherapy as second-line treatment of patients with advanced NSCLC. This meta-analysis, with 847 patients and 642 events, has a statistical power of 80% of recognizing a HR of 0.8 for combination chemotherapy. Our data show that doublets determine a statistically significant increase in RR and in PFS. This increase in activity does not translate in increase in OS compared with single-agent treatment. This appears to be coherent with the results described in the different setting of first-line chemotherapy of advanced NSCLC, where much larger differences in RR and in time to progression are needed to predict a significant survival benefit.²¹

Systematic reviews and meta-analyses have been increasingly used in recent years, as a precious instrument of assessing and interpreting the results from different clinical trials conducted on the same topic. The object of this meta-analysis represents a good topic for this approach because limited sample size of each trial did not allow adequate power to detect potentially clinically relevant differences in efficacy between the two strategies. Four trials were phase II randomized trials,^{10-12,15} although three of these^{10-11,15} were designed as classical phase III trials. Classically, phase II randomized trials should not be planned to formally compare the treatments, but

Zoledronic acid-induced regression of multiple metastases at nonskeletal sites

Bisphosphonates have been shown to reduce skeletal complications in individuals with bone metastases secondary to a wide range of solid tumors including lung, breast, and prostate cancer [1]. They are widely administered as palliative agents together with chemotherapy, hormonal therapy, or irradiation [2]. In addition, several types of cancer cells including hematologic malignancies respond to bisphosphonates *in vitro*, with such effects having been attributed, at least in part, to inhibition of the Ras-signaling pathway [3]. We now report an unusual case in which tumors in visceral organs and soft tissues responded markedly to treatment with the bisphosphonate zoledronic acid (ZA) alone, with the performance status of the patient improving in the absence of chemotherapy.

A 69-year-old man with no significant past medical history presented with pain in his left hip joint at our hospital in January 2007. X-ray examination revealed an osteosynthetic change in his left femur, and a metastatic tumor in his left thigh bone was indicated. Positron emission tomography with 2-[fluorine-18]fluoro-2-deoxy-D-glucose (FDG-PET) revealed uptake of the tracer at multiple sites including the left femur, right rib, left scapula, bilateral adrenal glands, s.c. tissue of the right gluteal region, and abdominal lymph nodes (Figure 1A, left panel). Concomitant computed tomography (CT) revealed tumors of various sizes at multiple sites corresponding to those of tracer uptake, with enlargement of the left adrenal glands apparent from a diameter of 50.2 mm. Biopsy specimens were obtained from the putative tumor on the left femur and the s.c. nodule of the right buttock. On the basis of the morphological and immunohistochemical staining characteristics of the specimens, a histopathologic diagnosis of spindle cell carcinoma was made, but the primary site of the tumor was not determined. The patient's general condition was poor, and he had an Eastern Cooperative Oncology Group performance status of three at the time of diagnosis. Systemic chemotherapy was therefore not selected, and palliative care was commenced. Together with prescription of narcotics and 20 Gy of radiation




Figure 1. Positron emission tomographies with 2-[fluorine-18]fluoro-2-deoxy-D-glucose before (A, left panel) and after (A, right panel) zoledronic acid treatment, and the corresponding computed tomographies before (B, left panel) and after zoledronic acid treatment (B, right panel) are shown.

to the left femur, ZA (4 mg/body) was administered i.v. every 4 weeks to reduce bone pain. After 6 months, his general condition was dramatically improved and follow-up FDG-PET revealed decreased uptake of the tracer in metastases not only in bone including the right rib, which was not irradiated, but also in the adrenal glands, abdominal lymph nodes, and s.c. tissue of the right buttock (Figure 1A, right panel). Unexpectedly, CT revealed that tumors in the adrenal glands had shrunk markedly, with the diameter of the left gland having decreased from 50.2 mm (Figure 1B, left panel) to 26.4 mm (Figure 1B, right panel), and the s.c. tumor in the right buttock was no longer detectable.

As far as we are aware, there have been no other reports of a tumor at a nonskeletal site responding to bisphosphonate treatment alone. ZA was recently shown to have efficacy as a preventive agent for cancer recurrence in premenopausal women with early-stage breast cancer [4]. This previous study suggested that ZA was able to prevent cancer recurrence not only in bone but also in nonskeletal organs including the contralateral breast, lung, and liver. The present case supports the notion that ZA targets not only osteoclasts, a major contributor to the tumor microenvironment in bone, but also tumor cells themselves, as has been shown in preclinical studies [3]. Further clinical evaluation of ZA for treatment of cancer is warranted.

K. Okamoto, J. Tsurutani*, M. Terashima, I. Okamoto & K. Nakagawa

Department of Medical Oncology, Kinki University School of Medicine, Osakasayama, Osaka, Japan
(*E-mail: tsurutani_j@dotd.med.kindai.ac.jp)

references

- Rosen LS, Gordon D, Tchekmedyian NS et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. *Cancer* 2004; 100: 2613–2621.
- Aapro M, Abrahamsson PA, Body JJ et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. *Ann Oncol* 2008; 19: 420–432.
- Tassone P, Tagliaferri P, Viscomi C et al. Zoledronic acid induces antiproliferative and apoptotic effects in human pancreatic cancer cells *in vitro*. *Br J Cancer* 2003; 88: 1971–1978.
- Gnant M, Minieritsch B, Luschin-Ebengreuth G et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. *Lancet Oncol* 2008; 9: 840–849.

doi:10.1093/annonc/mdp026

Published online 10 March 2009

Sorafenib Inhibits Non-Small Cell Lung Cancer Cell Growth by Targeting B-RAF in *KRAS* Wild-Type Cells and C-RAF in *KRAS* Mutant Cells

Ken Takezawa,¹ Isamu Okamoto,¹ Kimio Yonesaka,¹ Erina Hatashita,¹ Yuki Yamada,¹ Masahiro Fukuoka,² and Kazuhiko Nakagawa¹

¹Department of Medical Oncology, Kinki University School of Medicine; ²Department of Medical Oncology, Kinki University School of Medicine, Sakai Hospital, Osaka, Japan

Abstract

Sorafenib is a multikinase inhibitor whose targets include B-RAF and C-RAF, both of which function in the extracellular signal-regulated kinase (ERK) signaling pathway but which also have distinct downstream targets. The relative effects of sorafenib on B-RAF and C-RAF signaling in tumor cells remain unclear, however. We have now examined the effects of sorafenib as well as of B-RAF or C-RAF depletion by RNA interference on cell growth and ERK signaling in non-small cell lung cancer (NSCLC) cell lines with or without *KRAS* mutations. Sorafenib inhibited ERK phosphorylation in cells with wild-type *KRAS* but not in those with mutant *KRAS*. Despite this difference, sorafenib inhibited cell growth and induced G₁ arrest in both cell types. Depletion of B-RAF, but not that of C-RAF, inhibited ERK phosphorylation as well as suppressed cell growth and induced G₁ arrest in cells with wild-type *KRAS*. In contrast, depletion of C-RAF inhibited cell growth and induced G₁ arrest, without affecting ERK phosphorylation, in cells with mutant *KRAS*; depletion of B-RAF did not induce G₁ arrest in these cells. These data suggest that B-RAF-ERK signaling and C-RAF signaling play the dominant roles in regulation of cell growth in NSCLC cells with wild-type or mutant *KRAS*, respectively. The G₁ arrest induced by either C-RAF depletion or sorafenib in cells with mutant *KRAS* was associated with down-regulation of cyclin E. Our results thus suggest that sorafenib inhibits NSCLC cell growth by targeting B-RAF in cells with wild-type *KRAS* and C-RAF in those with mutant *KRAS*. [Cancer Res 2009;69(16):6515–21]

Introduction

Lung cancer is the leading cause of cancer-related mortality worldwide (1). Treatment options are limited for patients with advanced metastatic lung cancer, with traditional cytotoxic chemotherapy conferring only a limited survival benefit. Target-based therapies are therefore being pursued as potential treatment alternatives. The RAS-RAF-mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) kinase-ERK signaling pathway is a promising therapeutic target given its central role in regulation of mammalian cell proliferation, relaying extracellular signals from ligand-bound receptor tyrosine kinases (RTK) at the cell surface to the nucleus via a cascade of specific phosphorylation events and

beginning with the activation of the small GTPase RAS (2). Much attention is thus being focused on the development of inhibitors of this pathway.

RAF was the first effector kinase downstream of RAS to be identified (3). To date, the most successful clinical inhibitor of RAF activity is sorafenib (Nexavar, BAY 43-9006), an orally available compound that has received approval by the U.S. Food and Drug Administration for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma. Sorafenib is also currently undergoing clinical evaluation for a variety of additional cancers, including non-small cell lung cancer (NSCLC; refs. 4–7).

The mutational status of *RAS* and *B-RAF* genes is thought to affect the sensitivity of tumor cell lines to sorafenib as a result of the inappropriate activation by such mutations of the MAPK pathway mediated by ERK (8, 9). The sensitivity of tumor cell lines with different *RAS* mutations to sorafenib is less well characterized than is that of those with *B-RAF* mutations (10–14). Despite promising results of clinical trials of sorafenib monotherapy in NSCLC patients (4–7), little is known of the possible differences in the sorafenib sensitivity of NSCLC cells according to the mutational status of *KRAS*. We have therefore now examined the effects of RAF inhibition on the growth of NSCLC cells with or without *KRAS* mutations and further investigated the mechanisms of such effects.

Materials and Methods

Cell culture and reagents. The human NSCLC cell lines NCI-H292 (H292), LK-2, Sq-1, NCI-H520 (H520), PC9, NCI-H1650 (H1650), HCC827, NCI-H1975 (H1975), A549, NCI-H460 (H460), NCI-H23 (H23), NCI-H358 (H358), and NCI-H1299 (H1299) were obtained from the American Type Culture Collection. Ma70 cells were obtained as previously described (15). All cells were cultured under a humidified atmosphere of 5% CO₂ at 37°C in RPMI 1640 (Sigma) supplemented with 10% fetal bovine serum. Sorafenib was kindly provided by Bayer Pharmaceutical, dissolved in DMSO, and stored in aliquots at –20°C.

Assay of anchorage-dependent cell growth [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay]. Cells were plated in 96-well flat-bottomed plates and cultured for 24 h before exposure to various concentrations of sorafenib for 72 h. TetraColor One (5 mmol/L tetrazolium monosodium salt and 0.2 mmol/L 1-methoxy-5-methyl phenazinium methylsulfate; Seikagaku) was then added to each well, and the cells were incubated for 3 h at 37°C before measurement of absorbance at 490 nm with a Multiskan Spectrum instrument (Thermo Labsystems). Absorbance values were expressed as a percentage of that for untreated cells, and the concentration of sorafenib resulting in 50% growth inhibition (IC₅₀) was calculated.

Assay of anchorage-independent colony formation in soft agar. Anchorage-independent cell proliferation in soft agar was assayed with the use of a CytoSelect 96-Well Cell Transformation Assay (Cell Biolabs). In brief, cells were cultured for 7 d in complete medium containing soft agar and various concentrations of sorafenib. The agar matrix was then solubilized, the cells were stained with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium

Requests for reprints: Isamu Okamoto, Department of Medical Oncology, Kinki University School of Medicine, 377-2 Ohno-higashi, Osaka-Sayama, Osaka 589-8511, Japan. Phone: 81-72-366-0221; Fax: 81-72-360-5000; E-mail: chi-okamoto@dotd.med.kindai.ac.jp.
©2009 American Association for Cancer Research.
doi:10.1158/0008-5472.CAN-09-1076

bromide (MTT) and lysed, and the absorbance at 570 nm was measured relative to that at a reference wavelength of 690 nm. Normalized absorbance values were expressed as a percentage of that for untreated cells, and the IC_{50} of sorafenib for inhibition of colony formation was calculated.

Cell cycle analysis. Cells were harvested, washed with PBS, fixed with 70% methanol, washed again with PBS, and stained with propidium iodide (0.05 mg/mL) in a solution containing 0.1% Triton X-100, 0.1 mmol/L EDTA, and RNase A (0.05 mg/mL). The stained cells ($\sim 1 \times 10^6$) were then analyzed for DNA content with a flow cytometer (FACSCalibur, Becton Dickinson) and ModFit software (Verity Software House).

Immunoblot analysis. Cells were washed twice with ice-cold PBS and then lysed in a solution containing 20 mmol/L Tris-HCl (pH 7.5), 150 mmol/L NaCl, 1 mmol/L EDTA, 1% Triton X-100, 2.5 mmol/L sodium pyrophosphate, 1 mmol/L phenylmethylsulfonyl fluoride, and 1 μ g/mL leupeptin. The protein concentration of lysates was determined with the Bradford reagent (Bio-Rad), and equal amounts of protein were subjected to SDS-PAGE on a 7.5% gel. The separated proteins were transferred to a nitrocellulose membrane, which was then exposed to 5% nonfat dried milk in PBS for 1 h at room temperature before incubation overnight at 4°C with rabbit polyclonal antibodies to human phosphorylated ERK (1:1,000 dilution; Santa Cruz Biotechnology), ERK (1:1,000 dilution; Santa Cruz Biotechnology), FLAG epitope (1:1,000 dilution; Cell Signaling Technology), B-RAF (1:1,000 dilution; Santa Cruz Biotechnology), C-RAF (1:1,000 dilution; Cell Signaling Technology), or β -actin (1:500 dilution; Sigma) or with mouse monoclonal antibodies to cyclin E (1:1,000 dilution; Santa Cruz Biotechnology). The membrane was then washed with PBS containing 0.05% Tween 20 before incubation for 1 h at room temperature with horseradish peroxidase-conjugated goat antibodies to rabbit (Sigma) or mouse (Santa Cruz Biotechnology) immunoglobulin G. Immune complexes were finally detected with chemiluminescence reagents (Perkin-Elmer Life Science).

Forced expression of KRAS-V12. An expression vector for FLAG-tagged human KRAS-V12 was constructed by inserting the corresponding cDNA into the pcDNA3 plasmid (Invitrogen). The expression vector was introduced into H1299 cells by transfection for 48 h with the use of the Lipofectamine 2000 reagent (Invitrogen).

Gene silencing. Cells were plated at 50% to 60% confluence in six-well plates or 25-cm² flasks and then incubated for 24 h before transient transfection for 48 h with small interfering RNAs (siRNAs) mixed with the Lipofectamine reagent. The siRNAs specific for B-RAF (5'-AGACAGGAUUCGAAUGAAA-3') or C-RAF (5'-CCUCACGCCUUCACCUUUA-3') mRNAs were obtained from Dharmacon, and a nonspecific siRNA (control) was obtained from Nippon EGT. The cells were then subjected to immunoblot analysis or flow cytometry.

Statistical analysis. Data were analyzed by Student's two-tailed *t* test. A *P* value of <0.05 was considered statistically significant.

Results

Sorafenib inhibits cell growth by inducing G₁ arrest in NSCLC cell lines independently of KRAS genotype. The various isoforms of RAF are the principal effectors of RAS in the ERK signaling pathway, and mutant RAS proteins trigger persistent activation of downstream effectors (3). To determine whether the mutational status of KRAS might affect the sensitivity of NSCLC cells to sorafenib, an inhibitor of the kinase activity of RAF (16), we first examined the effects of this drug on the anchorage-dependent growth of NSCLC cells with or without KRAS mutations by the MTT assay. Sorafenib inhibited cell growth with IC_{50} values ranging from 7.4 to 11.3 μ mol/L in NSCLC cells with wild-type KRAS and from 5.6 to 14.1 μ mol/L in those with mutant KRAS (Fig. 1A), values that are within the clinically relevant concentration range for this drug (17). This inhibitory effect of sorafenib in cells with wild-type KRAS also seemed to be independent of whether the cells contained a mutant version of the *epidermal growth factor receptor* (*EGFR*) gene. We next investigated the effects of sorafenib on anchorage-independent colony formation in soft agar, a more clinically relevant model of NSCLC cell





Figure 1. Effects of sorafenib on the growth of NSCLC cell lines classified according to KRAS and EGFR mutational status. *A*, the indicated NSCLC cell lines were cultured for 72 h in complete culture medium containing various concentrations of sorafenib, after which cell viability was assessed with the MTT assay and the IC_{50} values of sorafenib for inhibition of cell growth were determined. *B*, the indicated NSCLC cell lines were cultured for 7 d in complete medium containing soft agar and various concentrations of sorafenib, after which colony formation was evaluated and the IC_{50} values of sorafenib for inhibition of anchorage-independent cell proliferation were determined. All data are means of triplicates from representative experiments that were repeated on three separate occasions.

proliferation. Sorafenib inhibited anchorage-independent colony formation with IC_{50} values of 5.6 to 11.1 μ mol/L in cells with wild-type KRAS and of 8.5 to 11.1 μ mol/L in those with mutant KRAS (Fig. 1B). These data thus indicated that sorafenib inhibits the growth of NSCLC cells in a manner independent of KRAS mutational status.

To investigate the mechanism by which sorafenib inhibits NSCLC cell growth, we examined the cell cycle profile by flow cytometry. Sorafenib increased the proportion of cells in G₁ phase of the cell cycle and reduced that of cells in S or G₂-M phases in all tested cell lines regardless of KRAS mutational status (Fig. 2). Sorafenib did not increase the proportion of cells in sub-G₁ phase, a characteristic of apoptosis. These data thus indicated that sorafenib inhibits cell growth by inducing arrest of the cell cycle in G₁ phase.

Effects of sorafenib on the ERK signaling pathway in NSCLC cell lines. To examine the effects of sorafenib on the ERK signaling pathway in NSCLC cells, we performed immunoblot analysis with antibodies specific for phosphorylated (activated) ERK. Sorafenib markedly inhibited ERK phosphorylation in cells with wild-type KRAS regardless of the mutational status of EGFR (Fig. 3A). In contrast, sorafenib had no effect on the level of ERK phosphorylation in cells

Figure 2. Effects of sorafenib on cell cycle distribution in NSCLC cells classified according to *KRAS* and *EGFR* status. Cells were incubated for 0, 24, or 48 h in complete culture medium containing 15 $\mu\text{mol/L}$ sorafenib and were then fixed, stained with propidium iodide, and analyzed for cell cycle distribution by flow cytometry. All data are means of triplicates from representative experiments that were repeated on three separate occasions.



with mutant *KRAS*. To investigate further whether the effect of sorafenib on ERK phosphorylation is dependent on *KRAS* mutational status, we introduced an expression vector for FLAG epitope-tagged *KRAS* with the activating Val¹² mutation (*KRAS-V12*) into the human NSCLC cell line H1299, which harbors wild-type endogenous *KRAS*. Whereas sorafenib inhibited ERK phosphorylation in nontransfected cells or cells transfected with the empty vector, it failed to do so in cells expressing *KRAS-V12* (Fig. 3B). These results thus suggested that sorafenib blocks the ERK signaling pathway only in NSCLC cells harboring wild-type *KRAS*.

B-RAF but not C-RAF depletion inhibits ERK phosphorylation in NSCLC cells with wild-type or mutant *KRAS*. The mammalian RAF family includes A-RAF, B-RAF, and C-RAF, all of which function in the ERK pathway but also have different downstream phosphorylation targets and play distinct roles in signaling (18). Although suggested to be a B-RAF inhibitor, sorafenib inhibits the activity of C-RAF with a potency 4-fold that apparent for B-RAF (16). To investigate the downstream consequences of B-RAF and C-RAF signaling in NSCLC cells, we examined the effects of the depletion of these kinases with a siRNA-based approach. Immunoblot analysis revealed




Figure 3. Effects of sorafenib on ERK phosphorylation in NSCLC cells classified according to *KRAS* and *EGFR* status. **A**, cells were incubated for 2 h in the presence or absence of sorafenib (15 $\mu\text{mol/L}$), after which cell lysates (25 μg of soluble protein) were subjected to immunoblot analysis with antibodies to phosphorylated (*p-ERK*) or total forms of ERK. **B**, H1299 cells were transiently transfected (or not) for 48 h with an expression vector for FLAG-tagged *KRAS-V12* or with the corresponding empty vector and were then incubated for 2 h in the presence or absence of sorafenib (15 $\mu\text{mol/L}$). Cell lysates (25 μg of soluble protein) were then subjected to immunoblot analysis with antibodies to FLAG and to phosphorylated or total forms of ERK.




Figure 4. Effects of transient depletion of B-RAF or C-RAF on ERK phosphorylation in NSCLC cells. Cells harboring wild-type or mutant *KRAS* were transfected with nonspecific (control), B-RAF, or C-RAF siRNAs for 48 h, after which cell lysates were prepared and subjected to immunoblot analysis with antibodies to B-RAF, C-RAF, phosphorylated ERK, and β -actin (loading control).

that transfection of NSCLC cells with siRNAs specific for B-RAF or C-RAF mRNAs resulted in marked and selective depletion of the corresponding protein (Fig. 4). Such depletion of B-RAF resulted in inhibition of ERK phosphorylation in cells harboring wild-type or mutant *KRAS*, whereas depletion of C-RAF had no such effect (Fig. 4). These data thus suggested that depletion of B-RAF, but not that of C-RAF, inhibits ERK phosphorylation regardless of *KRAS* status.

Effects of RAF depletion on NSCLC cell proliferation. We next examined the effects of B-RAF or C-RAF depletion on NSCLC cell proliferation and cell cycle distribution. Depletion of B-RAF resulted in significant inhibition of cell proliferation (Fig. 5A) and an increase in the proportion of cells in G₁ phase of the cell cycle (Fig. 5B), whereas depletion of C-RAF had no such effects, in NSCLC cells harboring wild-type *KRAS*. In contrast, depletion of C-RAF induced significant inhibition of cell proliferation (Fig. 5A) and an increase in the proportion of cells in G₁ phase (Fig. 5B), whereas depletion of B-RAF had only a less pronounced effect on cell proliferation, in NSCLC cells with mutant *KRAS*. These data thus suggested that B-RAF-ERK signaling regulates cell proliferation in NSCLC cells with wild-type *KRAS*, whereas C-RAF signaling mediates such regulation in NSCLC cells with mutant *KRAS*.

Sorafenib or C-RAF depletion inhibits cyclin E expression in NSCLC cells with mutant *KRAS*. Finally, to characterize further the growth inhibition and G₁ arrest induced by C-RAF depletion or sorafenib in NSCLC cells with mutant *KRAS*, we examined the expression of cyclin E, an essential promoter of the transition from G₁ to S phase of the cell cycle (19). Immunoblot analysis revealed that depletion of C-RAF in A549 or H460 cells resulted in pronounced inhibition of cyclin E expression, whereas depletion of B-RAF had no such effect (Fig. 6). Exposure of the cells to sorafenib also induced loss of cyclin E (Fig. 6). These results thus suggest that the G₁ arrest induced by depletion of C-RAF or by sorafenib in NSCLC cells with mutant *KRAS* may be attributable to the down-regulation of cyclin E.

Discussion

RAS is an upstream component of the ERK signaling pathway, which is aberrantly activated by oncogenic mutations of RAS genes. Among RAS family genes, mutations of *KRAS* are most common in solid malignancies, including NSCLC (8, 20, 21). Indeed, *KRAS* mutations have been associated with poor prognosis and resistance

to conventional cytotoxic chemotherapy in NSCLC (22–24). Whereas EGFR tyrosine kinase inhibitors are most efficacious in NSCLC patients with *EGFR* mutations, *KRAS* mutations are associated with resistance to these agents (25–28). The development of therapeutic strategies for NSCLC patients with *KRAS* mutations is thus an important clinical goal. RAF serine-threonine kinases are the principal effectors of RAS in the ERK signaling pathway. Given the key role of this pathway in tumor growth, RAF is a potential target for cancer therapy.

Sorafenib is an orally available compound that has been developed as a multikinase inhibitor with activity against RAF and several RTKs. The sensitivity of cancer cells to sorafenib might be expected to be affected by *KRAS* status, given that *KRAS* mutations result in activation of the ERK pathway (8). However, as far as we are aware, no previous study has compared sorafenib sensitivity among a panel of tumor cell lines of different *KRAS* mutational status. We have now evaluated the effects of sorafenib on the growth of NSCLC cells harboring wild-type or mutant forms of *KRAS* with two different assay systems, the MTT assay and anchorage-independent colony formation assay, given that previous studies have revealed differences in the sensitivity of cells to tested drugs between these two assay systems (29). The IC₅₀ values for inhibition of cell growth by sorafenib in these assays have generally been found to be well below 15 μ mol/L, the maximum achievable plasma concentration of this drug (17). We found that the potency of sorafenib for inhibition of cell growth was similar for NSCLC cells regardless of *KRAS* mutational status in both assay systems. We also performed a longer-term clonogenic survival assay and again found that sorafenib inhibited the survival of NSCLC cells regardless of *KRAS* status (data not shown). These results thus indicate that sorafenib inhibits the growth of NSCLC cells with mutant *KRAS* as well as it does that of those with wild-type *KRAS* in a clinically relevant concentration range.

We have shown that sorafenib inhibited ERK phosphorylation and induced G₁ arrest in NSCLC cells with wild-type *KRAS*, consistent with previous results obtained with several cancer cell lines harboring wild-type *KRAS* (13, 30, 31). Inhibition of the ERK signaling pathway, as reflected by a reduced level of ERK phosphorylation, results in inhibition of cell proliferation and induction of G₁ arrest in various cell types (32–35). In the present study, we found that depletion of B-RAF by RNA interference also inhibited ERK phosphorylation as well as attenuated cell proliferation and induced G₁ arrest in NSCLC cells with wild-type *KRAS*. These results suggest that inhibition of B-RAF-ERK signaling contributes to suppression of the growth of NSCLC cells harboring wild-type *KRAS* by sorafenib. Consistent with these findings, the specific B-RAF inhibitor SB-590885 was previously shown to inhibit ERK phosphorylation and to induce G₁ arrest in melanoma cells with wild-type *KRAS* (36, 37). In contrast, we found that depletion of C-RAF did not result in inhibition of ERK phosphorylation in NSCLC cells. ERK activation was previously shown to be conserved in cells derived from C-RAF knockout mice, suggesting that C-RAF is dispensable for ERK signaling (38, 39). Together, the present data suggest that B-RAF-ERK signaling, rather than C-RAF signaling, is a potential therapeutic target in NSCLC cells with wild-type *KRAS*.

We showed that ERK phosphorylation was not inhibited by sorafenib in two NSCLC cell lines (A549 and H460) harboring mutant *KRAS*, consistent with previous observations (16). We further showed this to be the case in two additional such cell lines (H358 and H23). Such results were previously suggested to be due to the existence of RAF-independent ERK activation in

NSCLC cells with mutant *KRAS* (16). However, we have now shown that B-RAF depletion resulted in inhibition of ERK activation in these cells. Our data therefore suggest that sorafenib is not able to attenuate the constitutive activation of the B-RAF-ERK pathway characteristic of NSCLC cells harboring mutant *KRAS* (40). Despite the sustained activation of B-RAF-ERK signaling in such cells, sorafenib inhibited cell proliferation and induced G₁ arrest in NSCLC cells with mutant *KRAS* as well as in those with wild-type *KRAS*. These data suggest that sorafenib targets a different pathway in its inhibitory effect on cell growth in NSCLC cells with mutant *KRAS*. Whereas sorafenib inhibits the kinase activity of both B-RAF and C-RAF, it shows a higher affinity for C-RAF (16). We found that depletion of C-RAF by RNA interference inhibited cell proliferation and induced G₁ arrest, without affecting ERK phosphorylation, in NSCLC cells with mutant *KRAS*, whereas it did not exhibit such effects in NSCLC cells harboring wild-type *KRAS*. Depletion of B-RAF also inhibited the growth of NSCLC cells with mutant *KRAS*, although this effect was not as pronounced as that in those with wild-type *KRAS*.

These data indicate that NSCLC cells with mutant *KRAS* are dependent on C-RAF signaling to a greater extent than on B-RAF-ERK signaling for cell proliferation but that both pathways participate in regulation of the growth of these cells. Melanoma cells that have acquired resistance to a specific B-RAF inhibitor were recently shown to have switched their dependency from B-RAF to C-RAF (41). These observations suggest that RAF proteins are functionally interchangeable in the regulation of cell growth. Our data thus indicate that C-RAF signaling is a potential therapeutic target in NSCLC cells with mutant *KRAS*. RAF family proteins are also implicated in regulation of cell cycle progression in a manner independent of the ERK pathway (18, 38, 42, 43). C-RAF has been shown to exist in a complex with Cdc25, which activates the cyclin E-Cdk2 complex and promotes the G₁-S phase transition (44, 45). Cyclin E is thus postulated to be a downstream effector of C-RAF. In the present study, we found that either C-RAF depletion or sorafenib treatment induced G₁ arrest and down-regulation of cyclin E in NSCLC cells with mutant *KRAS*. Although we cannot exclude a possible role for other cell cycle

Figure 5. Effects of B-RAF or C-RAF depletion on cell proliferation and cell cycle distribution in NSCLC cells. **A**, cells harboring wild-type or mutant *KRAS* were transfected with nonspecific (control), B-RAF, or C-RAF siRNAs for the indicated times, after which the number of viable cells was determined by staining with trypan blue. The number of viable cells is expressed relative to the value for time 0. Points, mean values from three independent experiments; bars, SD. *, *P* < 0.05 versus the corresponding value for cells transfected with the nonspecific siRNA. **B**, cells were transfected as in **A** for 48 h, fixed, stained with propidium iodide, and analyzed for cell cycle distribution by flow cytometry. The percentage of cells in G₁ phase is indicated. Data are from representative experiments that were repeated on three separate occasions.

